المؤلفون: G V Ershov, A V Chernavin, D N Bochkarev, Ya G Alekseeva, I V Smolenov

المصدر: Гинекология, Vol 4, Iss 5, Pp 210-216 (2002)

مصطلحات موضوعية: инфекции мочевыводящих путей, антибактериальная терапия, ингибиторзащищенные аминопенициллины, беременность, Gynecology and obstetrics, RG1-991

وصف الملف: electronic resource

Relation: https://gynecology.orscience.ru/2079-5831/article/view/27461; https://doaj.org/toc/2079-5696; https://doaj.org/toc/2079-5831

URL الوصول: https://doaj.org/article/582ca170b19148bab50b5c874ffc01b0

المؤلفون: V. I. Petrov, I. V. Smolenov, O. A. Alikova, N. A. Smirnov, F. I. Abazova, В. И. Петров, И. В. Смоленов, О. А. Аликова, Н. А. Смирнов, Ф. И. Абазова

المصدر: PULMONOLOGIYA; № 2 (2000); 62-70 ; Пульмонология; № 2 (2000); 62-70 ; 2541-9617 ; 0869-0189

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/3079/2484; Балаболкин И.И. Современная концепция патогенеза и терапии бронхиальной астмы у детей / / Педиатрия. 1995.— N5. С.73— 77.; Бронхиальная астма. Глобальная стратегия. Совместный доклад Национального института Сердце, Легкие, Кровь и Всемирной организации здравоохранения// Пульмонология. 1996. Прил.—С.1 — 166.; Бронхиальная астма у детей. Стратегия лечения и профилактика: Национальная программа. М.,— 1997.; Горячкина Л. А. Тайлед и его место в лечении бронхиальной астмы / / Аптека и больница. 1996. N 1. С. 2024.; Колганова Н.А. Интал и его аналоги в лечении бронхиальной астмы / / Бронхиальная астма / Под ред. А.Г.Чучалина. М., 1997.— Т.2.— С.330—340.; Стандартизация легочных функциональных тестов. Доклад рабочей группы "Стандартизация тестов легочной функции". Официальный отчет Европейского респираторного общества. М.: Пульмонология, 1993.; Чучалин А.Г., Антонов Н.С., Сахарова Г.М. и др. Метод оптимизации антиастматической терапии. М., 1997.; Bisgard Н. Use of inhaled corticosteroids in pediatric asthma / / Pediatr.Pulmonol. 1997.— Vol. 7. Suppl. 15.— P.27— 33.; Foucard T. Aggressive treatment of childhood asthma with local steroids. Good or bad? / / Allergy.— 1996.— Vol.51, N 6.— P. 367—371.; Holgate S.Т., Anderson K.D., Rodgers E.M. Comparison of 'Accolate' (zafirlukast) with sodium cromoglycate in mild to moderate asthmatic patients / / Ibid.— 1995. Vol.50 Suppl.26. P.319—320.; Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung and Blood Institute, National Institute of Health.— Bethesda, 1997.; Juniper E.F., Guyatt G.H., Ferrie P.J., Griffith L.E. Measuring quality of life in asthma / / Am.Rev.Respir.Dis. 1993.— Vol. 147.— P.832—838.; McConnell W., Howarth P. The airway antiinflammatory effects of fluticasone propionate / / Rev.Contemp. Pharmacother. 1998.— Vol.9.— P.523—532.; Pedersen S. Safety aspects of corticosteroids in children / / Eur. Respir. Rev.— 1994.— Vol.4, N 17.— P. 33—43.; Price J.F. Inhaled corticosteroids: clinical relevance of safety measures / / Pediatr. Pulmonol. — 1997. — Vol.7. — Suppl. 15. — P.40—45.; Russell G. Inhaled corticosteroid therapy in children: An assessment of the potential for side effects / / Thorax. 1994. Vol.49, N 12.— P. 1185— 1188.; Williams J. Fluticasone propionate in the treatment of asthma in children: Efficacy and safety / / Rev.Contemp. Pharmacother. 1998.— Vol.9.— P.581—587.; https://journal.pulmonology.ru/pulm/article/view/3079

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/3079

المؤلفون: V. I. Petrov, I. V. Smolenov, N. A. Smirnov, В. И. Петров, И. В. Смоленов, Н. А. Смирнов

المصدر: PULMONOLOGIYA; № 3 (1998); 88-95 ; Пульмонология; № 3 (1998); 88-95 ; 2541-9617 ; 0869-0189

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/3267/2663; Геппе Н.А., Карпушина А.В., БольшаковаТ.Д., Бутанян А.Ф. Эффективность ингаляционных кортикостероидов при бронхиальной астме у детей / / Рос. вестн. перинатол. и педиатр.— 1997.— № 4.— С.39—43.; Abuekteish F., Kirkpatrick J.N., Russell G. Posterior subcapsular cataract and inhaled corticosteroid therapy / / Thorax.— 1995.— Vol.50, № 6.— P.674—676.; Agertoft L., Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children / / Respir. Med.— 1994.— Vol.88, № 5.— P.373—381.; Agertoft L., Pedersen S. Bone growth and collagen markers in children treated with fluticasone propionate and budesonide (abstract) / / Eur. Respir. J.— 1996.— Vol.9, Suppl.23.— P.295S.; Agertoft L., Pedersen S. Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: A dose response study / / Ibid.— 1997.— Vol. 10, № 7.— P.1507—1512.; Allen D.B., Mullen M.L., Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth / / J. Allergy Clin. Immunol.— 1994.— Vol.93, № 6.— P.967—976.; Augusti M.B., Clara P.C. Dysphonia induced by corticoid inhalation. Truth or myth? / / Arch. Bronconeumol.— 1995.— Vol.31, No 8.— P.415—417.; Balfour-Lynn L. Growth and childhood asthma / / Arch. Dis. Child.— 1998.— Vol.61.— P.1049—1055.; Baraldi E., Bollini M.C., De Marchi A. et al. Effect of beclomethasone dipropionate on bone mineral content assessed by X-ray densitometry in asthmatic children: A longitudinal evaluation / / Eur. Respir. J.— 1994.— Vol.7, № 4.— P.710—714.; Barnes N.C. Safety of high-dose inhaled corticosteroids / / Respir. Med.— 1993.— Vol.87, Suppl.A.— P.27—31.; Bisgaard H., Nielsen M.D., Andersen B. et al. Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide / / J. Allergy Clin. Immunol.— 1988.— Vol.81.— P.1088—1095.; Bisgaard H. Systemic activity of inhaled topical steroid in toddlers studied by knemometry / / Acta Paediatr. Int. J. Paediatr.— 1993.— Vol.82, № 2.— P.1066—1071.; Bisgaard H. Use of inhaled corticosteroids in pediatric asthma / / Pediatr. Pulmonol.— 1997.— Suppl. 15.— P.27—33.; Boner A.L., Piacentini G.L. Inhaled corticosteroids in children: Is there a ‘safe’ dosage? / / Drug Saf.— 1993.— Vol.9, № 1.— P.9—20.; Clark D.J., Clark R .A., Lipworth B.J. Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children / / Thorax.— 1996.— Vol.51.— P.941—943.; Crowley S., Fiindmarsh P.C., Holownia P. et al. The use of low doses of ACTH in the investigation of adrenal function in man / / J. Endocrinol.— 1991.— Vol.130.— P.425—429.; Crowley S., Fiindmarsh P.C., Matthews D.R., Brook C.G. Growth and the growth hormone axis in prepubertal children with asthma / / J. Pediatr.— 1995.— Vol.126, № 2.— P.297—303.; Doull I.J.M., Freezer N.J., Flolgate S.T. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate / / Am. J. Respir. Crit. Care Med.— 1995.— Vol.151, No 6.— P.1715—1719.; Eseverry J.L., Botey J., Marin A.M. Budesonide: Treatment of bronchial asthma during childhood / / Allerg. Immunol.— 1995.— Vol.27, № 4.— P.129—135.; Estelle F., Simons R., Persaud M.P. et al. Absence of posteior subcapsular cataracts in young patients treated with inhaled glucocorticoids / / Lancet.— 1993.— Vol.342, № 8874 — P.776—778.; Gustafsson P., Tsanakas J., Gold M. et al. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 mu g/day with inhaled beclomethasone dipropionate 400 mu g/day in mild and moderate asthma / / Arch. Dis. Child.— 1993.— Vol.69, N° 2 — P.206—211.; Harris T.A.J., Fuller R.W. High dose fluticasone propionate (FP) and its effect on serum cortisol (sCORT) in patients with asthma / / Eur. Respir. J.— 1996.— Vol.9, Suppl.23.— P.163S—164S.; Hoekstra M.O., Grol M.H., Boutnan K. et al. Fluticasone propionate in children with moderate asthma / / Am. J. Respir. Crit. Care Med.— 1996.— Vol.154, № 4.— Pt 1.— P.1039—1044.; Hoekx J.C., Hedlin G., Pedersen W. et al. Fluticasone propionate compared with budesonide: A double-blind trial in asthmatic children using powder devices at a dosage of 400 mu g/day (-1) / / Eur. Respir. J.— 1996.— Vol.9, № 11.— P.2263—2272.; Honour J.W., Kelnar C.J.H., Brook C.G.D. Urine steroid excretion rates in childhood reflect growth and activity of adrenal cortex / / Acta Endocrinol.— 1990.— Vol. 14.— P.219—224.; Hopp R.J., Degan J.A.,Biven R.E. et al. Longitudinal assessment of done mineral density in children with chronic asthma / / Ann. Allegy Asthma Immunol.— 1995.— Vol.75.— P. 143—148.; Konig P., Hillman L., Cercantes C. et al. Bone metabolism in children with asthma treated inhaled beclomethasone / / J Pediatr.— 1993.— Vol.122.— P.219—236.; Konig P. Evidence for benefits of early intervention with nonsteroidal drugs in asthma / / Pediatr. Pulmonol.— 1997.— Suppl.15.— P.34—39.; Le Bourgeois M., Cormier C., Kindermans C. et al. Inhaled beclomethasone and bone metabolism in young asthmatic children: a six month study / / J. Allergy Clin. Immunol.— 1995.— Vol.96.— P.565—567.; Levy J., Zalkinder I., Kuperman O. et al. Effect of prolonged use of inhaled steroid on the cellular immunity of children with asthma / / Ibid.— Vol.95, No 4.— P.806—812.; Lipworth B.J., Clark D.J., McFarlane L.C. Adrenocortical activity with repeated daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children / / Thorax.— 1997.— Vol.52, № 8.— P.686—689.; Lorentzen K.A., Van Helmond J.L., Bauer K. et al. Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr / / Respir. Med.— 1996.— Vol.90, № 10.— P.609—617.; Mackenzie C.A., Wales J.K.H. Knemometry and its practical application / / Eur. Respir. Rev.— 1993.— Vol.3, № 13.— P.321—325.; Martinati L.C., Boner A.L. Inhaled corticosteroids in childhood: Risk and benefit / / Riv. Ital. Pediatr.— 1995.— Vol.21, № 1.— P. 16—29.; Martinati L.C., Bertoldo F., Gasperi E. et al. Effect on cortical and trabecular bone mass of different anti- inflammatory treatments in preadolescent children with chronic asthma / / Am. J. Respir. Crit. Care Med.— 1996.— Vol. 153, № 1.— P.232—236.; Nicolaizik W.H., Marchant J.L., Preece M.A. Endocrine and lung function in asthmatic children on inhaled corticosteroids / / Ibid.— 1994.— Vol. 150, N i 3.— P.624—628.; Ninan T.K., Russell G. Asthma, inhaled corticosteroid treatment, and growth / / Arch. Dis. Child.— 1992.— Vol.67, № 6.— P.703—705.; Pedersen S. Safety aspects of corticosteroid in children / / Eur. Respir. Rev.— 1994.— Vol.4, № 17.— P.33—43.; Pedersen S. Important issues in childhood asthma / / Ibid.— 1996.— Vol.6, No 37.— P.192—198.; Piacentini G.L., Sette L., Peroni D.G. et al. Double-blind evaluation of efectiveness and safety of flunisolide aerosol for treatment of bronchial asthma in children / / Allergy'.— 1990.— Vol.45, № 8.— P.612—616.; Preice J.F., Russell G., Hindmarsh P. et al. Grewth velocity in asthmatic children receiving fluticasone propionate 50 meg bd or sodium cromoglycate 20 mg qds (abstract) / / Eur. Respir. J.— 1996.— Vol.9, Suppl.23.— P.294S.; Price J.F. Inhaled corticosteroids: chinical relevance of safety measures / / Pediatr. Pulmonol.— 1997.— Suppl. 15.— P.40—45.; Schoni M.Y. Security and side effects of steroid inhalation therapy in children with bronchial asthma / / Schweiz. Rundsch. Med. Prax.— 1995.— Bd 84, № 40.— S.l108—1113.; Sorva R., Tahtela R., Turpeinen M. et al. Changes in bone markers in children with asthma during inhaled budesonide and nedocromil treatments / / Acta Paediatr. Int. J. Paediatr.— 1996.— Vol.85, № 10.— P.l176—1180.; Tabachnik E., Zadik Z. Diurnal cortisol secretion during therapy with inhaled beclomethasone dipropionate in children with asthma / / J. Pediatr.— 1991.— Vol.118.— P.294—297.; Thomas B.C., Stanhope R., Grant D.B. Impairment growth in children with asthma during treatment with conventional doses on inhaled corticosteroids / / Acta Paediatr. Int. J. Paediatr.— i 994.— Vol.83, № 2.— P.196—199.; Todd G., Dunlop K., McNaboe J. et al. Growth and adrenal supression in asthmatic children treated with high dose fluticasone propionate / / Lancet.— 1996.— Vol.348.— P.27—29.; Volovitz b., Kauschansky A., Nussinovitch M. et al. Normal diurnal variation in serum cortisol concentration in asthmatic children treated with inhaled budesonide / / J. Allergy Clin. Immunol.— 1995.— Vol.96, № 6.— Pt II.— P.874—878.; Wolthers O.D., Pedersen S. Short term linear growth in asthmatic children during treatment with prednisolone / / Br. Med. J.— 1990.— Vol.301, № 6744.— P.145—148.; Wolthers O.D., Pedersen S. Growth of asthmatic children during treatment with budesonide: A double blind trial / / Ibid.— 1991.— Vol.303, № 6795.— P. 163—165.; Wolthers O.D., Pedersen S. Controlled study of linear growth in asthmatic children during treatment with inhaled glucocorticosteroids / / Pediatrics.— 1992.— Vol.89, № 5.— P.839—842.; Wolthers O.D., Pedersen S. Short term growth during treatment with inhaled fluticasone propionate and beclomethasone diproprionate / / Arch. Dis. Child.— 1993.— Vol.68, № 5.— P.673—676.; Wolthers O.D., Juul A ., Hansen M. et al. The insulin-like growth factor axis and collagen turnover in asthmatic children treated with inhaled budesonide / / Acta Paediatr. Int. J. Paediatr.— 1995.— Vol.84.— P.393—397.; Wolthers O.D. Long-, intermediate- and short-term growth studies in asthmatic childern treated with inhaled glucocorticosteroids / / Eur. Respir. J.— 1996.— Vol.9, № 4.— P.821—827.; https://journal.pulmonology.ru/pulm/article/view/3267

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/3267

المؤلفون: I. V. Smolenov, L. M. Ogorodova, S. A. Stakhanova, Yu. A. Petrovskaya, N. A. Ivanova, N. G. Mashukova, V. R. Lipina, N. A. Smirnov, Yu. Yu. Zima, И. В. Смоленоев, Л. М. Огородова, С. А. Стаханова, Ю. А. Петровская, Н. А. Иванова, Н. Г. Машукова, В. Р. Липина, Н. А. Смирнов, Ю. Ю. Зима

المصدر: PULMONOLOGIYA; № 2 (2002); 50-57 ; Пульмонология; № 2 (2002); 50-57 ; 2541-9617 ; 0869-0189

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/2918/2324; Стандартизация легочных функциональных тестов. Доклад рабочей группы "Стандартизация тестов легочной функции". Официальный отчет "Европейского респираторного общества". М .: Пульмонология; 1993.; Чучалин А.Г., С колов A.C., Пашкова T.Л. и др. Опыт применения пролонгированного р2.симпатомиметика сальметерола у больных бронхиальной астмой. Пульмонология 1996; 2: 79-83.; Шмушкович Б.И. Клиническая эффективность и механизмы противовоспалительного действия глюкокортикоидных гормонов в лечении больных бронхиальной астмой. В кн.: Ч у чалин А.Г. (ред.) Бронхиальная астма. М .; 1997; Т.2: 224-253.; Bleecker E.R., Welch M.J., Weinstein S.F. et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J. Allergy Clin. Immunol. 2000; 105 (6, pt 1): 1123-1129.; Juniper E.F., Guyatt G.H., Willan A., Griffith L.E . Determining a minimal important change in a disease-specific quality of life questionnaire. J. Clin. Epidemiol. 1994; 47 (1): 81-87.; Kelly K.D., Spooner С.И., Rowe B.H. Nedocromil sodium vs cromoglycate for preventing exercise induced bronchoconstriction in asthma. (Cochrane review). In: The Cochrane library. Oxford: Update Software; 2000; issue 3.; Pdersen S. Safety aspects of corticosteroids in children. Eur. Respir. Rev. 1994; 4 (17): 33-43.; Pollard S.J., Spector S.L., Yancey S.W . et al. Salmeterol versus theophylline in the treatm ent of asthma. Ann. Allergy Asthma Immunol. 1997; 78 (5): 457-464.; Rufin P., Scheinmann P., De-Blic J. Exercise-induced asthma. Diagnosis, prophylaxis and treatment. BioDrugs 1997; 8 (1 ): 6-15.; Taylor W.R., Newacheck P.W. Impact of childhood asthma on health. Pediatrics 1992; 90: 657-662.; https://journal.pulmonology.ru/pulm/article/view/2918

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/2918

المؤلفون: A. G. Chuchalin, A. S. Belevsky, I. V. Smolenov, N. A. Smirnov, Ya. G. Alexeeva, А. Г. Чучалин, А. С. Белевский, И. В. Смоленов, Н. А. Смирнов, Я. Г. Алексеева

المصدر: PULMONOLOGIYA; № 1 (2004); 67-83 ; Пульмонология; № 1 (2004); 67-83 ; 2541-9617 ; 0869-0189

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/2434/1886; What is quality of life? — 2000; 1 (9): 1-6.; Wiklund /., Dimenas E., Wahl M. Factors of importance when evaluating quality of life in clinical trials. Control. Clin. Trials 1990; 11: 169-179.; The WHOQOL group. Wld Hlth Forum 1996; 17: 354-356.; Бронхиальная астма: руководство для врачей России. Формулярная система. Прил. к журн. "Пульмонология"/Чучалин А.Г., Медников Б.Л., Белевский А.С. и др. М.; 1999.; Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert panel report. 2002.; Juniper E.F. Quality-of-life considerations in the treatment of asthma. PharmacoEconomics 1995; 8 (2): 123-138.; Bateman E.D., Bousquet J., Braunstein C.L. Is overall asthma control being achieved? A hypothesis-generating study. Eur. Respir. J. 2001; 17 (4): 589-595.; Ware J.E. SF-36 Health Survey. Manual and interpretation guide. Second printing. Boston, Massachusetts: The Health Institute. New England Medical Center; 1997.; Juniper E.F., Guyatt G.H., Ferrie P.J., Griffith L.E. Measuring quality of life in asthma. Am. Rev. Respir. Dis. 1993; 147: 832-838.; https://journal.pulmonology.ru/pulm/article/view/2434

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/2434

المؤلفون: V. l. Petrov, I. V. Smolenov, N. A. Smirnov, В. И. Петров, И. В. Смоленов, Н. А. Смирнов

المصدر: PULMONOLOGIYA; № 3 (2001); 99-107 ; Пульмонология; № 3 (2001); 99-107 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2001-0-3

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/2836/2247; Global initiative for asthma. Global strategy for asthma management and prevention. Publ. N 95—3659. Washington: National Heart, Lung and Blood Institute, National In stitu te s of Health; 1995.; International consensus report on diagnosis and management of asthma. NIH Publ. N. 92—3091. National Heart, Lung and Blood Institute, National Institute of Health. Bethesda, Md; 1992.; Greening A.P., Ind. P.W., Northfield М., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219.; Taylor D.M. et al. Current autp a tien t management of asthma shous poor compliance with International Consensus Inidelines. Chest 1999; 116 (6): 1638—1645.; Cabana M.D. et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. J.A.M.A. 1999; 282 (15): 1458—1465.; Chung K.F. The complementory role of glucocorticosteroids and long-acting P-adrenergic agonists. Allergy 1998; 53 (suppl.42): 7—13.; Eickelberg О Roth М., Lorx R. et al. Ligand-independent activation of glucocorticoid receptor by P2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. - 1999; 274: 1005.; Baraniuk L, Ali М., Brody D. et al. Glucocorticoids induce P2 - adrenergic receptor function in human nasal mucosa. Am. J. Respir. Crit. Care Med. 1997; 155: 704.; Pang L., Knox A.J. Synergistic inhibition by p 2-adrenoceptor agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smoothmuscle cells. Am. J. Respir. Cell Mol. Biol. 2000; 23: 79.; Pang L.H., Knox A.J. Inhibition by p 2 -adrenoceptor agonists and dexa-methasone on TNFalpha stimulated eotaxin release from human airway smooth muscle cells. Respir. Med. 1999; 54 (suppl.): A6.; Oddera S., Silvestri M ., Testi R., Rossi G.A. Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation. Respiration 1998; 65: 199.; Anenden V., Egemba G., Kessel B. et al. Salmeterol facilitation of fluticasone-induced apoptosis in eosinophils of asthmatics preand post-antigen challenge [abstract]. Eur. Respir. J. 1998; 12 (suppl. 28): 157s.; Mak J.C.W., Nishikawa М., Barnes P.J. Glucocorticosteroids increase p2 -adrenergic receptor transcription in human lung. Am. J. Physiol. 1995; 268: L41.; Mak J.C.W., Nishikawa М., Shirasaki H. et al. Protective effects of a glucocorticoid on downregulation of pulmonary p2-adrenergic receptors in vivo. J. Clin. Invest. 1995; 96: 99.; Proud D., Reynolds C.J., Lichtenstein L.M. et al. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Clin. Exp. Allergy. 1998; 28: 868.; Bissonnette E.Y., Befus D. Anti-inflammatory effect of p2 — agonists: inhibition of TNF-alpha release from human mast cells. J. Allergy Clin. Immunol. 1997; 100: 825.; Butchers P.R., Vardey C.J., Johnson M. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br. J. Pharmacol. 1991; 104: 672.; Nials A.T., Ball D.I., Butchers P.R. et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur. J. Pharmacol. 1994; 251: 127.; Chong L .K , Cooper E., Vardey C.J., Peachell P.T. Salmeterol inhibition of mediator release from human lung mast cells by ß-adrenoceptor-dependent and independent mechanisms. Br. J. Pharmacol. 1998; 123: 1009.; Dowling R.B., Johnson M., Cole P J ., Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur. Respir. J. 1998; 11: 86.; Dowling R.B., Rayner C.F.J., Rutman A. et al. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am. J. Respir. Crit. Care Med. 1997; 155: 327.; Chapman K.R., Ringdal N., Backer V. et al. Salmeterol and fluticasone propionate (5 0 /2 5 0 jig) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can. Respir. J. 1999; 6 (1): 45—51.; Bateman E.D., Britton M., Carrillo J. et al. S a lm e tero l/flu tic a - sone propionate combination inhaler: a new, effective and well tolerated tre a tm en t of asthma. Clin. Drug. Invest. 1998; 16: 193—201.; Adkins J.C., McTavish D. Salmeterol: review of its pharmacological properties and clinical efficacy in the management of children with asthma. Drugs 1997; 54: 331-354.; Holliday S .M., Flauds D., Sorkin E.M. Inhaled fluticasone propionate: a review of its pharmocodynamic and pharmacokinetic properties, and theraputic use in asthma. Drugs 1994; 47 (2): 318—331.; Jarvis B., Faulds D. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosage; Dahl R. Salmeterol and fluticasone propionate in the treatment of asthma symptoms. Eur. Respir. Rev. 1997; 7: 338—343.; Johnson M. Development of fluticasone propionate and comparison with o ther inhaled corticosteroids. J. Allergy Clin. Immunol. 1998; 101 (4, pt 2, supp l.1): S434—S439.; Spenser C.M., Jarvis B. Salmeterol/fluticasone propionate combination. Drugs 1999; 57: 933—940.; Shapiro G., Lumry W., Wolfe J. et al. Combined salmeterol 50 µg and fluticasone propionate 250 µg in the Diskus device for the treatment of asthma. Am. J. Respir. Crit. Care Med. 2000; 161: 527—534.; Man C.Y., Kirby S.M., McRae J. et al. Systemic pharmacodynamic effects of salmeterol in the salmeterol/FP combination Diskus inhaler [absract no. Р1073]. Eur. Respir. J. 1996: 9 (suppl.23): 164s.; Gross G., Woodring A., Prillaman В. et al. Efficacy and safety of the salmeterol / fluticasone propionate ( 50 / 100 µg) dry powder combination inhaler in patients with asthma. Ibid.1998; 12 (suppl. 28): 156s.; Salmeterol/fluticasone propionate prescribing information. Uxbridge: Glaxo; 1999 Jul 27: 7.; Aubier M., Pieters W.R., Schlosser N.J.J. et al. Salmeterol/fluticasone propionate (50/500 µg) in combination in a Diskus inhaler (Seretid) is effective and safe in the treatment of steroiddependent asthma. Respir. Med. 1999; 93: 876-884.; Van de Berg N.J., Ossip M.S., Hederos C.A. et al. Salmeterol / fluticasone propionate (50/100 µg) in combination in a Diskus™ inhaler (Seretid™) is effective and safe in children with asthma. Pediatr. Pulmonol. 2000; 30: 97—105.; Kavuru M., Melamed J., Greoss G. et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the tre a tm en t of asthma: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 2000; 105 (6, pt 1): 1108—1116.; LaForce C., Woodring A., Baitinger L. et al. Salmeterol 50 mcg /fluticasone propionate lOOmcg Diskus combination product demo n s tra tes improvements in lung function regardless of baseline corticosteroid therapy [abstract no. 35]. Ibid. (1, pt 2): S I2.; Pearlman D., Baitinger L., Woodring A. et al. Salmeterol 50 mcg/fluticasone propionate 250 mcg Diskus combination product demonstrates improvements in lung function regardless of baseline corticosteroid therapy [abstract]. Am. J. Respir. Crit. Care Med. 2000; 161 (3, pt 2): A 196.; Wolfe J., Bell T., Raphael G. et al. Efficacy of the salmeterol/fluticasone propionate dry powder combination product in the Diskus: a stratified study in patients on salmeterol alone or inhaled corticosteroids [abstract no. 879]. J. Allergy Clin. Immunol. 1999: 103.(1, pt 2): S228.; Reese P.R., Mahajan P., Woodring A. Salmeterol/fluticasone propionate combination product improves quality of life in asthma patients [abstract no. P0325] Eur. Respir. J. 1998; 12 (suppl.28): 35s.; Reese P.R., Mather D.B., Mahajan P. et al. Combination of salmelerol/fluticasone propionate via Diskus improves quality of life in asthma patients. J. Allergy Clin. Immunol. 1999; 103 (1, pt 2): 69.; Jenkins C., Woolcock A.J., Saarelainen P. et al. Salmleterol/fluticasone propionate combination therapy 50/250 µg twice daily is more effective than budesonide 800 µg twice daily in treating moderate to severe asthma. Respir. Med. 2000: 94: 715—723.; Jenkins C., Woolcock A., Saarelainen P. et al. Advair/Seretide (satmeterol 50 mcg / fluticasone propionate 250 mcg bid) compared with budesonide (800 mcg bid) during he first week of treatment of moderate asthma [abstract no. 493]. J. Allergy Clin. Immunol. 2000; 105 (1, pt 2): S 161.; Juniper E.F., Jenkins C., Price M.J. et al. Quality of life of asthma patients treated with salmeterol/fluticasone propionate combination product and budesonide. In: Annual Congress European respiratory society. Madrid, 1999, Oct. 9—13. Madrid; 1999. abstr. no. P2460.; Ringdal N., Chuchalin A.G., Chovan L. et al. A comparison of Advair/Seretide (salmeterol 50 (mcg)/fluticasone propionate 250 (mcg bid) with formoterol 12 (mcg) + budesonid 800 (mcg bid in moderate-severe asthma [abstract]. Am. J. Respir. Crit. Care Med. 2000; 161 (3): A 196.; Nelson H.S., Busse W.W., Kerwin E. et al. Fluticasone propionate / salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J. Allergy Clin. Immunol. 2000; 106 (6): 1088—1095.; Lundback B., Pieters W.R.{ Johansson G. et al. Cost-effectiveness analyses of s a lm e te ro l/flu tic a so n e propionate combination product and fluticasone propionate in patients with a sthma. I: Introduction and overview. PharmacoEconomics 1999; 16 (suppl.2): 1—8.; Pieters W.R., Lundback B., Johansson G. et al. Cost-effectiveness analyses of sa lm e te ro l/flu tic a so n e propionate combination product and fluticasone propionate in patients with asthma. II: Study methodologies. Ibid. 9—14.; Johansson G., Price M.J., Sondhi S. Cost-effectiveness analysis of salmeterol/ fluticasone propionate 50/100 mg vs fluticasone propionate 100 M g in adults and adolescents with asthma III: Results. Ibid. 15—21.; Palmqvist M., Price M.J., Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250 mg vs fluticasone propionate 250 mg in adults and adolescents with asthma IV: Results. Ibid. 23—28; Pieters W.R., Lundback B., Sondhi S. et al. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/500 µg vs fluticasone propionate 500 jig in adults and adolescents with asthma V: Results. Ibid. 29—34.; Lundback B., Jenkins C., Price M.J., Thwaites M.A. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micrograms twice daily and budesonide 800 micrograms twice daily in the tre a tm en t of adults and adolescents with asthma. Respir. Med. 2000; 94: 724.; Pieters W.R., Wilson K.K., Smith H.C.E., Tamminga J.J. Costeffectiveness of fluticasone propionate/salmeterol combination product and fluticasone propionate / montelukast in asthma. Am. J. Respir. Crit. Care Med. 2001; 163 (5, pt 2): A643.; Advair Diskus (fluticasone propionate and salmeterol) product information. Glaxo Wellcome Inc. Research. Triangle Park. NC; 2000 Aug: 30.; British National Formulary. No. 40. London: The Pharmaceutical Press; 2000. 772.; Ashurst I.C., Gordon P. Consistent dose delivery from a new metered dose inhaler contaning a combination of salmeterol and fluticasone propionate in HFA 134A [ab strac t no. P2295]. Eur. Respir. J. 1999; 14 (suppl.30): 341S.; British Thoracic Society, National Asthma Compaign, Royal College of Phyisicians of London, et al. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52 (supp l.l): S I—S21.; Bateman E.D., Bousquet Braunstein G.L. Is overall asthma control being achieved? A hypothesis-generating study. Eur. Respir. J. 2001; 17: 589—595.; Nielsen L.P., Pedersen B., Faurschou P. et al. Salmeterol reduces the need for inhaled corticosteroid in steroid dependent asthmatics. Respir. Med. 1999; 93 (12): 863—868.; Clark N., Jones P., Keller S., Vermeire P. Patient factors and compliance with asthma therapy. Ibid. 856—862.; https://journal.pulmonology.ru/pulm/article/view/2836

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/2836

المؤلفون: V I, Petrov, A S, Vekel'yan, A V, Martyushev, S A, Sergeeva, I V, Smolenov, O I, Epstein

المصدر: Bulletin of experimental biology and medicine. 135

مصطلحات موضوعية: Adult, Male, Middle Aged, Antibodies, Piperazines, Sildenafil Citrate, Young Adult, Treatment Outcome, Double-Blind Method, Erectile Dysfunction, Purines, Humans, Sulfones, Aged

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::256d687e1385ae45daeb9eb5d6927092
https://pubmed.ncbi.nlm.nih.gov/12949684

المؤلفون: A. S. Vekel'yan, I. V. Smolenov, Oleg I. Epstein, V. I. Petrov, A. V. Martyushev, Svetlana Alexandrovna Sergeeva

المصدر: Bulletin of Experimental Biology and Medicine. :150-151

مصطلحات موضوعية: medicine.medical_specialty, Clinical effectiveness, business.industry, Sildenafil, Urology, General Medicine, Pharmacology, medicine.disease, Placebo, General Biochemistry, Genetics and Molecular Biology, Endothelial no synthase, law.invention, chemistry.chemical_compound, Erectile dysfunction, chemistry, Randomized controlled trial, law, medicine, In patient, business, Test preparation

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ff5007fb5af7a06199ebd8df8aa66fc3
https://doi.org/10.1023/a:1024796611758

المؤلفون: N A, Mikhaĭlova, V K, Tatochenko, I V, Smolenov

المصدر: Europe PubMed Central

مصطلحات موضوعية: Clinical Trials as Topic, Vaccines, Drug Design, Research, Humans, Guidelines as Topic, Drug Approval, Russia

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c3674efe6bd34296f3acff4e6ce3ecaa
http://europepmc.org/abstract/med/17297878